We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.
- Authors
Auweiler, Philipp W P; Müller, Dirk; Stock, Stephanie; Gerber, Andreas
- Abstract
The monoclonal antibody rituximab has shown clinical effectiveness in combination with chemotherapy for the treatment of non-Hodgkin's lymphoma (NHL) in several randomized controlled studies. Rituximab maintenance therapy is associated with significant improvement in progression-free and overall survival in patients with NHL. However, treatment with rituximab causes considerable costs for healthcare systems.
- Publication
PharmacoEconomics, 2012, Vol 30, Issue 7, p537
- ISSN
1179-2027
- Publication type
Journal Article
- DOI
10.2165/11591160-000000000-00000